Opendata, web and dolomites

SUSPENCE

SUSPension ENvironment for CEll culture

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 SUSPENCE project word cloud

Explore the words cloud of the SUSPENCE project. It provides you a very rough idea of what is the project "SUSPENCE" about.

commercialisation    parts    rotation    morphological    space    patent    commercialization    financial    deadline    tests    received    manual    competing    firms    tank    scalability    drug    global    large    cellular    months    protected    vitro    confirmed    solutions    market    labour    2d    microgravity    cells    september    forecast    commercial    monitoring    damaging    interventions    requirement    release    cell    biological    complexity    manufacturing    solution    thrice    strategies    standardization    industrialization    revenues    excellence    size    dimensional    bioreactor    conventional    financially    start    moving    italian    basic    labs    suspence    operation    explanatory    amounts    pilots    capacity    advantages    dynamic    bioreactors    damage    expand    unsustainable    chamber    contamination    biotech    maturity    rotating    customers    suffer    stirred    36    grow    disease    suspension    intensive    limitations    red    mainly    seal    benefits    3rd    mechanism    november    perfusion    total    technological    2018    innovative    irr    larger    international    practically    48    74    keeps    productivity    culture   

Project "SUSPENCE" data sheet

The following table provides information about the project.

Coordinator
BIOCOM - BIOMEDICAL COMPONENTS SRL 

Organization address
address: PIAZZALE DELLE BELLE ARTI, 2
city: ROMA
postcode: 196
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Italy [IT]
 Project website http://www.cellexpansiondevices.com/home.html
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-06-01   to  2019-11-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    BIOCOM - BIOMEDICAL COMPONENTS SRL IT (ROMA) coordinator 50˙000.00

Map

 Project objective

Large-scale production of cells is essential for basic research, disease modelling and drug testing. However, scalability and standardization in cellular manufacturing are still major challenges: when large numbers of cells are required, conventional two-dimensional (2D) culture strategies, mainly based on manual, space- and labour-intensive interventions, are practically and financially unsustainable. Dynamic suspension allows large-scale production of cells, but current solutions on the market suffer from limitations in terms of cells damaging and potential contamination (stirred tank bioreactors) or high cost and complexity (rotating bioreactors). The SUSPENCE solution is a microgravity perfusion bioreactor, a highly innovative technological system that keeps cells in suspension in the culture chamber, allowing them to grow and reach maturity in dynamic conditions with no rotation mechanism or moving parts. SUSPENCE benefits have been confirmed by explanatory morphological and biological tests carried out on an in vitro cell culture. SUSPENCE advantages on competing solutions are: less cell damage, more easy-to-use, increased productivity, better monitoring and control and reduced operation costs. The design of SUSPENCE bioreactor is protected by an international patent application. The target users are research labs and red-biotech firms and; the market size has been estimated in over 6.000 potential customers in EU. Commercialization will start on the Italian market in 20 months from the start of the project, after pre-commercial pilots and industrialization, to expand on the EU market in 36 months and to reach the global market in month 48, after release of larger capacity devices. Forecast revenues are 9 M€/year in the 3rd year of commercialisation. The total financial requirement amounts to about 2.5 M€, with an IRR of 74%. SUSPENCE received thrice the “Seal of Excellence” by European Commission in 2018 (deadline of May, September, November).

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "SUSPENCE" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "SUSPENCE" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

DeltaQon (2019)

IOT and cloud computing for online medical analysis service platform

Read More  

PAROST (2019)

Disruptive technology for the identification, quantification and prediction of the evolution of damages in civil engineering structures that increases safety while reducing maintenance costs.

Read More  

Dyme (2019)

Dyme gives its users complete control over their financial situation. The Dyme application provides insight into users’ spending and subscriptions, and lets users cancel, negotiate, or switch any cont

Read More